Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys.
SARS-CoV-2
intranasal vaccine
live-attenuated viral vector
mucosal immmunization
nasal spray vaccine
next-generation COVID vaccine
parainfluenza virus
pediatric
pediatric COVID vaccine
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
08 Dec 2022
08 Dec 2022
Historique:
received:
20
05
2022
revised:
07
10
2022
accepted:
03
11
2022
pubmed:
25
11
2022
medline:
15
12
2022
entrez:
24
11
2022
Statut:
ppublish
Résumé
Pediatric SARS-CoV-2 vaccines are needed that elicit immunity directly in the airways as well as systemically. Building on pediatric parainfluenza virus vaccines in clinical development, we generated a live-attenuated parainfluenza-virus-vectored vaccine candidate expressing SARS-CoV-2 prefusion-stabilized spike (S) protein (B/HPIV3/S-6P) and evaluated its immunogenicity and protective efficacy in rhesus macaques. A single intranasal/intratracheal dose of B/HPIV3/S-6P induced strong S-specific airway mucosal immunoglobulin A (IgA) and IgG responses. High levels of S-specific antibodies were also induced in serum, which efficiently neutralized SARS-CoV-2 variants of concern of alpha, beta, and delta lineages, while their ability to neutralize Omicron sub-lineages was lower. Furthermore, B/HPIV3/S-6P induced robust systemic and pulmonary S-specific CD4
Identifiants
pubmed: 36423629
pii: S0092-8674(22)01418-0
doi: 10.1016/j.cell.2022.11.006
pmc: PMC9684001
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4811-4825.e17Informations de copyright
Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of interests X.L., C.L., C.L.N., S.M., and U.J.B. are inventors on the provisional patent application number 63/180,534, entitled “recombinant chimeric B/HPIV3 expressing SARS-CoV-2 spike protein and its use,” filed by the United States Department of Health and Human Services.
Références
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Curr Opin Pediatr. 2021 Feb 1;33(1):114-121
pubmed: 33278112
J Immunol. 2007 Apr 15;178(8):4721-5
pubmed: 17404250
Science. 2021 Sep 17;373(6561):eabj0299
pubmed: 34529476
Cell. 2022 Apr 28;185(9):1549-1555.e11
pubmed: 35427477
PLoS Pathog. 2021 Jul 19;17(7):e1009668
pubmed: 34280241
Immunity. 2021 Jan 12;54(1):14-18
pubmed: 33406391
Cell Rep Med. 2021 Apr 20;2(4):100230
pubmed: 33754147
J Virol. 2000 Oct;74(19):8922-9
pubmed: 10982335
Lancet Microbe. 2020 May;1(1):e14-e23
pubmed: 32835326
Science. 2021 Nov 19;374(6570):913
pubmed: 34793207
Mucosal Immunol. 2022 Mar;15(3):379-388
pubmed: 34671115
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
J Gen Virol. 2006 Jun;87(Pt 6):1691-1695
pubmed: 16690935
Nat Commun. 2020 Aug 21;11(1):4207
pubmed: 32826924
Sci Immunol. 2022 Mar 10;:eabo0535
pubmed: 35271298
N Engl J Med. 2020 Oct 15;383(16):1544-1555
pubmed: 32722908
Mucosal Immunol. 2017 Jan;10(1):260-270
pubmed: 27049058
Sci Transl Med. 2022 Feb 16;14(632):eabi5735
pubmed: 34914540
mBio. 2021 Aug 31;12(4):e0150321
pubmed: 34311582
Nature. 2020 Oct;586(7830):567-571
pubmed: 32756549
Cell Rep Med. 2021 Jul 20;2(7):100355
pubmed: 34230917
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Immunity. 2021 Apr 13;54(4):797-814.e6
pubmed: 33765436
Clin Infect Dis. 2021 Dec 6;73(11):e4433-e4443
pubmed: 32681645
Sci Transl Med. 2021 Aug 18;13(607):
pubmed: 34315826
Proc Natl Acad Sci U S A. 2021 Dec 14;118(50):
pubmed: 34876520
J Virol. 1999 Jan;73(1):251-9
pubmed: 9847328
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Front Immunol. 2019 Jul 02;10:1400
pubmed: 31312199
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9
pubmed: 15210961
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288661
JAMA Netw Open. 2022 Jan 4;5(1):e2142322
pubmed: 35015063
Vaccine. 2012 Jun 6;30(26):3975-81
pubmed: 22178099
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Pediatr Infect Dis J. 2012 Feb;31(2):109-14
pubmed: 21926667
Biochem Biophys Res Commun. 2021 Jan 29;538:211-217
pubmed: 33190827
Nat Immunol. 2021 Oct;22(10):1306-1315
pubmed: 34417590
J Virol. 2004 Apr;78(7):3572-7
pubmed: 15016880
J Virol. 2014 Apr;88(8):4237-50
pubmed: 24478424
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
J Virol. 2001 May;75(10):4594-603
pubmed: 11312329
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
J Clin Virol. 2020 Mar;124:104261
pubmed: 31954277
Sci Immunol. 2021 Nov 19;6(65):eabl9105
pubmed: 34618554
Sci Immunol. 2021 Dec 10;6(66):eabj5129
pubmed: 34890255